IP-PA1 (Immunopotentiator from Pantoea agglomerans 1)
Also known as: IP-PA1, Pantoea agglomerans LPS, fermented flour extract, edible lipopolysaccharide
Effective Dosage
No established dose from human clinical trials
What the Science Says
IP-PA1 is a lipopolysaccharide (LPS) — a molecule from the outer membrane of a bacterium called Pantoea agglomerans, which naturally lives in wheat and other crops. In animal and cell studies, it activates macrophages, the immune system's frontline patrol cells, which may help the body fight infections, reduce allergic reactions, and resist stress-related immune suppression. Most research has been done in mice, fish, and cell cultures, with no published human clinical trials confirming these effects.
What It Doesn't Do
Not proven to treat cancer, diabetes, or any disease in humans. Animal results don't automatically translate to people. No human dosing guidelines exist. Don't expect it to replace chemotherapy or standard allergy treatments. The broad list of claimed benefits — tumors, ulcers, malaria, stress — is based almost entirely on animal research.
Evidence-Based Benefits
IP-PA1 is a lipopolysaccharide (LPS) — a molecule from the outer membrane of a bacterium called Pantoea agglomerans, which naturally lives in wheat and other crops. In animal and cell studies, it activates macrophages, the immune system's frontline patrol cells, which may help the body fight infections, reduce allergic reactions, and resist stress-related immune suppression. Most research has been done in mice, fish, and cell cultures, with no published human clinical trials confirming these effects.
Weak EvidenceEffective at: No established dose from human clinical trials
Source: auto-research
Absorption & Bioavailability
Unknown in humans. Animal studies suggest oral administration reaches immune tissues and activates macrophages, but human absorption and distribution data are not available from the provided studies.
Red Flags to Watch For
- All efficacy data comes from animal models (mice, fish, chickens) and cell cultures — no human clinical trials have been published in the provided research
- LPS compounds from bacteria can trigger dangerous inflammatory responses (sepsis) at high doses; the safety profile in humans at supplement doses is not well established
- The bacterium Pantoea agglomerans is also documented as a cause of occupational allergic and immunotoxic diseases — people with sensitivities should be cautious
- Extremely broad health claims (cancer, diabetes, malaria, stress, allergy) with no human RCT evidence is a major marketing red flag
- No registered supplement products found in NIH DSLD, suggesting limited regulatory oversight of commercial products
Products Containing IP-PA1 (Immunopotentiator from Pantoea agglomerans 1)
See how IP-PA1 (Immunopotentiator from Pantoea agglomerans 1) is used in these analyzed products:
Research Sources
- PubMed
- NIH DSLD
This information is for educational purposes only and is not medical advice. Always consult a healthcare professional before starting any supplement regimen. Last updated: 2026-04-08